Korean Drug Co., Ltd. (KOSDAQ:014570)

Korean Drug Statistics

Total Valuation

Korean Drug has a market cap or net worth of KRW 38.08 billion. The enterprise value is 3.63 billion.

Market Cap	38.08B
Enterprise Value	3.63B

Important Dates

The last earnings date was Thursday, May 28, 2026.

Earnings Date	May 28, 2026
Ex-Dividend Date	Dec 29, 2025

Share Statistics

Korean Drug has 10.91 million shares outstanding.

Current Share Class	10.91M
Shares Outstanding	10.91M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	50.60%
Owned by Institutions (%)	n/a
Float	5.39M

Valuation Ratios

The trailing PE ratio is 5.51.

PE Ratio	5.51
Forward PE	n/a
PS Ratio	0.61
PB Ratio	0.46
P/TBV Ratio	0.46
P/FCF Ratio	3.58
P/OCF Ratio	3.43
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 0.39, with an EV/FCF ratio of 0.34.

EV / Earnings	0.52
EV / Sales	0.06
EV / EBITDA	0.39
EV / EBIT	0.50
EV / FCF	0.34

Financial Position

The company has a current ratio of 6.63, with a Debt / Equity ratio of 0.00.

Current Ratio	6.63
Quick Ratio	5.07
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.01
Interest Coverage	1,843.01

Financial Efficiency

Return on equity (ROE) is 8.67% and return on invested capital (ROIC) is 11.96%.

Return on Equity (ROE)	8.67%
Return on Assets (ROA)	4.86%
Return on Invested Capital (ROIC)	11.96%
Return on Capital Employed (ROCE)	8.52%
Weighted Average Cost of Capital (WACC)	5.44%
Revenue Per Employee	232.45M
Profits Per Employee	25.60M
Employee Count	270
Asset Turnover	0.67
Inventory Turnover	1.91

Taxes

In the past 12 months, Korean Drug has paid 1.43 billion in taxes.

Income Tax	1.43B
Effective Tax Rate	17.14%

Stock Price Statistics

The stock price has decreased by -30.29% in the last 52 weeks. The beta is 0.22, so Korean Drug's price volatility has been lower than the market average.

Beta (5Y)	0.22
52-Week Price Change	-30.29%
50-Day Moving Average	3,950.20
200-Day Moving Average	4,230.03
Relative Strength Index (RSI)	22.61
Average Volume (20 Days)	20,958

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Korean Drug had revenue of KRW 62.76 billion and earned 6.91 billion in profits.

Revenue	62.76B
Gross Profit	27.43B
Operating Income	7.29B
Pretax Income	8.34B
Net Income	6.91B
EBITDA	9.25B
EBIT	7.29B
Earnings Per Share (EPS)	n/a

Balance Sheet

The company has 34.54 billion in cash and 83.07 million in debt, with a net cash position of 34.46 billion or 3,157.75 per share.

Cash & Cash Equivalents	34.54B
Total Debt	83.07M
Net Cash	34.46B
Net Cash Per Share	3,157.75
Equity (Book Value)	82.31B
Book Value Per Share	n/a
Working Capital	61.18B

Cash Flow

In the last 12 months, operating cash flow was 11.10 billion and capital expenditures -466.77 million, giving a free cash flow of 10.63 billion.

Operating Cash Flow	11.10B
Capital Expenditures	-466.77M
Depreciation & Amortization	1.97B
Net Borrowing	-79.08M
Free Cash Flow	10.63B
FCF Per Share	974.42

Margins

Gross margin is 43.71%, with operating and profit margins of 11.61% and 11.01%.

Gross Margin	43.71%
Operating Margin	11.61%
Pretax Margin	13.29%
Profit Margin	11.01%
EBITDA Margin	14.74%
EBIT Margin	11.61%
FCF Margin	16.94%

Dividends & Yields

This stock pays an annual dividend of 160.00, which amounts to a dividend yield of 4.71%.

Dividend Per Share	160.00
Dividend Yield	4.71%
Dividend Growth (YoY)	12.50%
Years of Dividend Growth	2
Payout Ratio	28.18%
Buyback Yield	n/a
Shareholder Yield	4.71%
Earnings Yield	18.15%
FCF Yield	27.92%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Korean Drug has an Altman Z-Score of 4.83 and a Piotroski F-Score of 5.

Altman Z-Score	4.83
Piotroski F-Score	5